New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia

Expert Review of Neurotherapeutics

Volumn 13, Issue 7, 2013, Pages 767-783

  Citrome, Leslie ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Adherence; Antipsychotic; Aripiprazole; Depot; fluphenazine; Haloperidol; Long acting injection; Olanzapine; Paliperidone; Risperidone; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; FLUPHENAZINE ENANTHATE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; RISPERIDONE;

AGE; AGGRESSION; AGITATION; AKATHISIA; BRIEF PSYCHIATRIC RATING SCALE; CASE MANAGEMENT; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; COST CONTROL; DELIRIUM; DELUSION; DISORIENTATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RESPONSE; DRUG STORAGE; DRUG TOLERABILITY; DYSPEPSIA; FAMILY RELATION; FATIGUE; FINLAND; GAIT DISORDER; GENDER; HALLUCINATION; HEALTH CARE COST; HOSPITAL READMISSION; HOSPITALIZATION; HOSTILITY; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MONOTHERAPY; MOTOR DYSFUNCTION; PACKAGING; PARKINSONISM; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERSECUTORY DELUSION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RISK REDUCTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLURRED SPEECH; SMOKING; SOCIAL SUPPORT; STORAGE TEMPERATURE; SUBSTANCE ABUSE; SUICIDE; SUICIDE ATTEMPT; TRAFFIC AND TRANSPORT; UNCONSCIOUSNESS; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; HUMANS; INJECTIONS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84883199833     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2013.811984     Document Type: Review

References (74)

1. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin. Pharmacother. 10(12), 1917-1928 (2009).
2. Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J. Clin. Psychiatry 67(10), 1542-1550 (2006).
3. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr. Clin. North Am. 30(3), 437-452 (2007).
4. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 63(12), 1121-1128 (2002).
5. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 63(10), 892-909 (2002).
6. Weiden P, Rapkin B, Zygmunt A, Mott T, Goldman D, Frances A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr. Serv. 46(10), 1049-1054 (1995).
7. Weiden PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J. Clin. Psychiatry 68(Suppl. 14), 14-19 (2007).
8. Velligan DI, Wang M, Diamond P et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr. Serv. 58(9), 1187-1192 (2007).
9. Velligan DI, Lam YW, Glahn DC et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr. Bull. 32(4), 724-742 (2006).
10. Ahn J, McCombs JS, Jung C et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health 11(1), 48-56 (2008).
11. Velligan DI, Weiden PJ, Sajatovic M et al.; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 70(Suppl. 4), 1-46; quiz 47 (2009).
12. Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J. Clin. Psychiatry 69(1), 47-53 (2008).
13. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr. Serv. 55(8), 886-891 (2004).
14. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 8, 32 (2008).
15. Lindenmayer JP, Liu-Seifert H, Kulkarni PM et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J. Clin. Psychiatry 70(7), 990-996 (2009).
16. Alia-Klein N, O'Rourke TM, Goldstein RZ, Malaspina D. Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggress. Behav. 33(1), 86-96 (2007).
17. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol. Drug Saf. 12(5), 423-424 (2003).
18. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J. Clin. Psychiatry 67(3), 453-460 (2006).
19. Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J. Clin. Psychiatry 64(Suppl. 12), 5-19 (2003).
20. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J. Clin. Psychiatry 67(Suppl. 5), 15-18 (2006).
21. Patel MX, DE Zoysa N, Baker D, David AS. Antipsychotic depot medication and attitudes of community psychiatric nurses. J. Psychiatr. Ment. Health Nurs. 12(2), 237-244 (2005).
22. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 127(1-3), 83-92 (2011).
23. Kishimoto T, Robenzadeh A, Leucht C et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr. Bull. doi:10.1093/ schbul/sbs150 (2013) (Epub head of print).
24. Kishimoto T, Nitta M, Borenstein M, Jane JM, Correll CU. Long acting injectable vs. oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror image studies. Neuropsychopharmacology 38(Suppl.), S417-S418 (2012).
25. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry 168(6), 603-609 (2011).
26. Peng X, Ascher-Svanum H, Faries D, Conley RR, Schuh KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon. Outcomes Res. 3, 9-14 (2011).
27. Citrome L, Levine J, Allingham B. Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol. Bull. 32(3), 321-326 (1996).
28. Barnes TR, Shingleton-Smith A, Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. Br. J. Psychiatry. Suppl. 52, S37-S42 (2009).
29. West JC, Marcus SC, Wilk J, Countis LM, Regier DA, Olfson M. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr. Bull. 34(5), 995-1001 (2008).
30. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking firstgeneration depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr. Serv. 58(4), 482-488 (2007).
31. Citrome L, Jaffe A, Levine J. Data points: depot antipsychotic use in New York Statehospitals, 1994 to 2009. Psychiatr. Serv. 61(1), 9 (2010).
32. Warikoo N, Schwartz TL, Citrome L. Depot antipsychotics. In:Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention . Schwartz TL, Megna JL, Topel ME (Eds). Nova Science Publishers, NY, USA (2013).
33. Fluphenazine decanoate injection, USP, package insert. APP Pharmaceuticals, LLC, IL, USA. 34 Citrome L, Jaffe A, Levine J. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities. Schizophr. Res. 119(1-3), 153-159 (2010).
34. Kane JM, Rifkin A, Woerner M et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch. Gen. Psychiatry 40(8), 893-896 (1983).
35. David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J. Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst. Rev. 1, CD000307 (2005).
36. Beresford R, Ward A. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 33(1), 31-49 (1987).
37. HaldolR Decanoate 50, HaldolR Decanoate 100 (haloperidol), package insert. Ortho-McNeil-Janssen Pharmaceuticals, Inc., NJ, USA. 39 Quraishi S, David A. Depot haloperidol decanoate for schizophrenia. Cochrane Database Syst. Rev. 2, CD001361 (2000).
38. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br. J. Psychiatry. Suppl. 52, S13-S19 (2009).
39. Ehret MJ, Fuller MA. Long-acting injectable risperidone. Ann. Pharmacother. 38(12), 2122-2127 (2004).
40. Harrison TS, Goa KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 18(2), 113-132 (2004).
41. Chue P. Risperidone long-acting injection. Expert Rev. Neurother. 3(4), 435-446 (2003).
42. RisperdalR ConstaR (risperidone) long-acting injection, package insert. Ortho-McNeil-Janssen Pharmaceuticals, Inc., NJ, USA. 45 Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 160(6), 1125-1132 (2003).
43. Chue P, Eerdekens M, Augustyns I et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur. Neuropsychopharmacol. 15(1), 111-117 (2005).
44. Simpson GM, Mahmoud RA, Lasser RA et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 67(8), 1194-1203 (2006).
45. Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J. Clin. Psychiatry 70(2), 196-200 (2009).
46. InvegaR SustennaR (paliperidone palmitate) extended-release injectable suspension, package insert. Janssen Pharmaceuticals, Inc., Beerse, Belgium. 50 Citrome L. Paliperidone palmitate-review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int. J. Clin. Pract. 64(2), 216-239 (2010).
47. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin. Pharmacokinet. 48(9), 585-600 (2009).
48. Pandina GJ, Lindenmayer JP, Lull J et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J. Clin. Psychopharmacol. 30(3), 235-244 (2010).
49. Gopal S, Hough DW, Xu H et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int. Clin. Psychopharmacol. 25(5), 247-256 (2010).
50. Nasrallah HA, Gopal S, Gassmann-Mayer C et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 35(10), 2072-2082 (2010).
51. Kramer M, Litman R, Hough D et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int. J. Neuropsychopharmacol. 13(5), 635-647 (2010).
52. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 116(2-3), 107-117 (2010).
53. Fleischhacker WW, Gopal S, Lane R et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int. J. Neuropsychopharmacol. 15(1), 107-118 (2012).
54. Pandina G, Lane R, Gopal S et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(1), 218-226 (2011).
55. Johnson & Johnson. Pharmaceutical Research & Development, LLC. Protocol no. CR003562. A randomized, doubleblind, placebo-controlled, parallel group, dose-response study to evaluate the efficacy and safety of 3 fixed doses (25 mg eq., 50 mg eq., and 100 mg eq.) of paliperidone palmitate in subjects with schizophrenia. Clinical Study Report Synopsis, document no. EDMS-PSDB-6481158:2.0, 7 September 2007. 60 Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst. Rev. 6, CD008296 (2012).
56. Citrome L. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. Patient Prefer. Adherence 3, 345-355 (2009).
57. ZyprexaR Relprevv (olanzapine) extended release injectable suspension, package insert. Eli Lilly and Co., IN, USA. 63 Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int. J. Clin. Pract. 63(1), 140-150 (2009).
58. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J. Clin. Psychiatry 69(5), 790-799 (2008).
59. Kane JM, Detke HC, Naber D et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am. J. Psychiatry 167(2), 181-189 (2010).
60. Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Expert Opin. Drug Saf. 7(6), 761-769 (2008).
61. Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin. Drug Investig. 31(7), 455-482 (2011).
62. McDonnell DP, Kryzhanovskaya LA, Zhao F, Detke HC, Feldman PD. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. Hum. Psychopharmacol. 26(6), 422-433 (2011).
63. Detke HC, McDonnell DP, Brunner E et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 10, 43 (2010).
64. McDonnell DP, Detke HC, Bergstrom RF et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry 10, 45 (2010).
65. Abilify Maintena (aripiprazole) extended release injectable suspension, package insert. Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.
66. Kane JM, Sanchez R, Perry PP et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 73(5), 617-624 (2012).
67. Fleischhacker WW, Sanchez R, Perry PP et al. Aripiprazole once-monthly for the treatment of schizophrenia: a double-blind randomized, non-inferiority study vs. oral aripiprazole. Neuropsychopharmacology 38(Suppl.), S339 (2012).
68. Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr. Dis. Treat. 2(4), 427-443 (2006).
69. Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin. Pharmacother. 13(11), 1599-1613 (2012).
70. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657), 31-41 (2009).
71. Leucht S, Komossa K, Rummel-Kluge C et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 166(2), 152-163 (2009).
72. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 14(4), 429-447 (2009).
73. Citrome L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin. Pharmacother. 13(11), 1545-1573 (2012).
74. Remington GJ, Adams ME. Depot neuroleptic therapy: clinical considerations. Can. J. Psychiatry. 40(3 Suppl. 1), S5-S11 (1995).